BioPharm International
October 01, 2003
Columns and Departments
16
10
Helium Out-Detects Soap and Water
October 01, 2003
Product Development Issues
16
10
Biotech companies are among the most intensive instrumentation users of any FDA-regulated business. Because of the complex nature of these companies' research and manufacturing, they typically have a larger number of instruments per employee.
October 01, 2003
Product Development Issues
16
10
With the biotechnology industry in the early phases of commercialization, many bioprocess companies are just beginning to build and operate commercial-scale production facilities.
October 01, 2003
Columns and Departments
16
10
New proposals encourage computerized systems and aim to simplify post-approval changes and avoid problems with sterile products.
October 01, 2003
Product Development Issues
16
10
Congratulations - your emerging biotechnology company is within sight of its first Biological License Application (BLA). This is the culmination of years of research and clinical development.
October 01, 2003
Columns and Departments
16
10
Outsourcing is in the public eye as politicians debate the lag in job growth despite a recovering economy, and the Bush Administration seeks to ?competitively source? more agency activities.
October 01, 2003
Product Development Issues
16
10
The biotechnology and pharmaceutical industries have some overriding concerns, namely regulatory and compliance issues, insufficient manufacturing capacity, and the economic challenges of producing niche drugs and therapies.
October 01, 2003
Product Development Issues
16
10
When analyzing data, you will sometimes find one value that is far from the others. Such a value is called an outlier. When you encounter an outlier, you may be tempted to delete it from the analysis. Assuming that the data point is not attributable to obvious experimental mistakes, do you keep it or delete it?